Anti-Mouse TIM-4 – Biotin

Extracellular domains of TIM-4 (aa 1-288)

This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.

Research Use Only

2 – 8° C Wet Ice

RMT4-53 activity is directed against mouse TIM-4.

The T cell immunoglobulin and mucin domain containing protein (TIM) family encodes cell surface receptors that are involved in the regulation of T helper (Th) -1 and -2 cell-mediated immunity¹. TIM-4, which is preferentially expressed on macrophages and dendritic cells, is the natural ligand of TIM-1, and this binding leads to T-cell expansion and cytokine production. Unlike other members of the TIM family, TIM-4 lacks a putative tyrosine phosphorylation signal sequence in its intracellular domain. The TIM-4 gene maps to a locus associated with predisposition to asthma in both mice and humans and with its connection to TIM-1-triggered Th2 responsiveness, may be considered as a candidate disease/predisposition gene for asthma.

RMT4-53 was generated by linking the extracellular domains of TIM-4 (aa 1-288) to the Fc portion of mouse IgG2a². This protein product was then used to immunize Sprague Dawley rats. Subsequently, LN cells were fused with P3U1 myeloma cells. RMT4-53 reacts with TIM-4/NRK cells but not with parental NRK or other TIM family members.

TIM-4 blockade has been investigated for the treatment of cancer^3,4 and allograft rejection^2,5 using anti-TIM-4 clone RMT4-53. Additionally, RMT4-53 blockade of TIM-4 leads to increased induction of iTregs from naïve CD4⁺ T cells². Blockade with RMT4-53 has also been investigated in liver ischemia-reperfusion injury^6,7.

TIM-4 is expressed by antigen-presenting cells of the lymphoid lineage, preferentially by mature dendritic cells and macrophages.

Phosphatidylserine, TIM1

1 Meyers JH, Chakravarti S, Schlesinger D, et al. Nat Immunol. 6(5):455-464. 2005.
2 Yeung MY, McGrath MM, Nakayama M, et al. J Immunol. 191(8):4447-4455. 2013.
3 Baghdadi M, Nagao H, Yoshiyama H, et al. Cancer Immunol Immunother. 62(4):629-637.2013.
4 Ding Q, Mohib K, Kuchroo VK, et al. J Immunol. 199(7):2585-2595. 2017.
5 Vergani A, Gatti F, Lee KM, et al. Cell Transplant. 24(8):1599-1614. 2015.
6 Ji H, Liu Y, Zhang Y, et al. Hepatology. 60(6):2052-2064. 2014.
7 Li J, Zhao X, Liu X, et al. Mol Immunol. 66(2):117-125. 2015.